Pages that link to "Q30636532"

The following pages link to Molecular pharmacology of human vasopressin receptors (Q30636532):

Displaying 34 items.

• Science review: Vasopressin and the cardiovascular system part 1--receptor physiology (Q21195090) (← links)
• Vasopressin V1a and V1b receptors: from molecules to physiological systems (Q26823378) (← links)
• Comparison of vasopressin binding sites in human uterine and vascular smooth muscle cells (Q28143964) (← links)
• Chapter 14 Molecular pharmacology and modeling of vasopressin receptors (Q29036235) (← links)
• Management of hyponatraemia in older people: old threats and new opportunities (Q33949221) (← links)
• Systemic diseases associated with disorders of water homeostasis (Q34677232) (← links)
• Tolvaptan, hyponatremia, and heart failure (Q35026759) (← links)
• Neuroendocrine pharmacology of stress. (Q35071526) (← links)
• Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist (Q35545067) (← links)
• Endogenous arginine vasopressin-positive retinal cells in arginine vasopressin-eGFP transgenic rats identified by immunohistochemistry and reverse transcriptase-polymerase chain reaction (Q35629053) (← links)
• Genetics of vasopressin receptors (Q35670641) (← links)
• A C-terminal segment of the V1R vasopressin receptor is unstructured in the crystal structure of its chimera with the maltose-binding protein (Q35950953) (← links)
• Oxytocin antagonists as potential therapeutic agents for the treatment of preterm labour (Q36477483) (← links)
• Oxytocin receptor signaling in myoepithelial and cancer cells (Q36522962) (← links)
• Vaptans and hyponatremia in critical patients (Q37058365) (← links)
• Diagnosis and management of hyponatremia in acute illness (Q37277688) (← links)
• Arginine vasopressin gene expression changes within the nucleus accumbens during environment elicited cocaine-conditioned response in rats (Q37440713) (← links)
• Neurosteroid biosynthesis: enzymatic pathways and neuroendocrine regulation by neurotransmitters and neuropeptides (Q37511056) (← links)
• Hyponatremia and the Use of Vasopressin Receptor Antagonists In Critically Ill Patients (Q37875586) (← links)
• Congenital nephrogenic diabetes insipidus: the current state of affairs (Q37994652) (← links)
• Unpredictable nature of tolvaptan in treatment of hypervolemic hyponatremia: case review on role of vaptans (Q38186712) (← links)
• The Changing Role of Sodium Management in Cirrhosis. (Q38796241) (← links)
• Ascites, refractory ascites and hyponatremia in cirrhosis (Q39323841) (← links)
• Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus (Q41960221) (← links)
• Conivaptan and its role in the treatment of hyponatremia (Q42108467) (← links)
• ACTH and cortisol responses to ghrelin and desmopressin in patients with Cushing's disease and adrenal enlargement (Q43168140) (← links)
• Bridged bicyclic vasopressin receptor antagonists with V(2)-selective or dual V(1a)/V(2) activity (Q44173859) (← links)
• The influence of vasopressin deficiency and acute desmopressin administration on melatonin secretion in patients with central diabetes insipidus. (Q44821248) (← links)
• V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. (Q45922591) (← links)
• Usefulness of desmopressin testing to predict relapse during long-term follow-up in patients in remission from Cushing's disease (Q47104748) (← links)
• The prognosis of heart failure patients: Does sodium level play a significant role? (Q58588044) (← links)
• Neuroendocrine Mechanisms Involved In Sexual And Emotional Behavior (Q64040898) (← links)
• Vascular effects of RWJ-676070, a selective combined V1a/V2 vasopressin receptor antagonist (Q79799636) (← links)
• Hyponatremia in patients with heart failure (Q86497446) (← links)